ARTICLE | Clinical News
Herpes simplex virus type 2: Phase II started
October 10, 2016 7:00 AM UTC
Vical began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 1 mL intramuscular VCL-HB01 every 28 days for 4 doses in about 225 patients. ...